Showing papers in "Blood in 2018"

TL;DR: Recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

TL;DR: The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.

TL;DR: The biology of the CD28/CTLA-4 pathway is focused on as a framework for understanding the impacts of therapeutic manipulation of this pathway.

TL;DR: After treatment with blinatumomab in a population of patients with MRd-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders.

TL;DR: The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

TL;DR: The final PACE results demonstrate ponatinib provides durable and clinically meaningful responses, irrespective of dose reductions, in this population of heavily pretreated CP-CML patients.

TL;DR: Sustained efficacy and acceptable tolerability of ibrutinib over an extended time is demonstrated, providing the longest experience for Bruton tyrosine kinase inhibitor treatment in patients with CLL/SLL.

TL;DR: Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis and the incidence of infections was comparable to observations from clinical trials of salvage chemoimmunotherapies in similar patients.

TL;DR: Deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors, and CD38-targeting antibodies are generally well tolerated and induce partial response or better in heavily pretreated MM patients as monotherapy.

TL;DR: Using integrated genomics of 1273 newly diagnosed patients with MM, associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits.

TL;DR: These recommendations include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.

TL;DR: Preclinical results suggest that targeting 4-1BB with agonist antibodies can lead to tumor clearance and durable antitumor immunity, and future agents show great promise for achieving potent immune activation while avoiding limiting immune-related adverse events.

TL;DR: Overall, 2 patients experienced complete remission at 54 mg/m2 per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in MLL-r leukemia patients.

TL;DR: Mechanisms and predictive biomarkers for PD-1 blockade immunotherapy, treatment-related adverse events, hyperprogression, and combination therapies are discussed in the context of B-cell lymphomas.

TL;DR: The findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.

TL;DR: ALT-803 is a safe, well-tolerated agent that significantly increased NK and CD8+ T cell numbers and function and warrants further investigation to augment antitumor immunity alone and combined with other immunotherapies.

TL;DR: A unique connection between MAS risk and chronic IL-18 is described, epithelial inflammasome hyperactivity is identified as a potential source, and the pathogenicity of free IL-16 is demonstrated, suggesting an IL- 18-driven pathway, complementary to the cytotoxic impairment of fHLH, with potential as a distinguishing biomarker and therapeutic target in MAS.

TL;DR: The combination of BV plus Nivo was an active and well-tolerated first salvage regimen, potentially providing patients with R/R HL an alternative to traditional chemotherapy.

TL;DR: It is argued that most of the causes that underlie HSC aging result from cell-intrinsic pathways, and reflect on which aspects of the aging process may be reversible.

TL;DR: A single infusion of AMT-060 had a positive safety profile and resulted in stable and clinically important increases in FIX activity, a marked reduction in spontaneous bleeds and FIX concentrate use, without detectable cellular immune responses against capsids.

TL;DR: Current concepts around anemias at older age are reviewed, with special emphasis on etiologies, clinical implications, and innovative concepts in the management of these patients.

TL;DR: A hitherto unrecognized immune evasion strategy mediated via skewing toward an exhausted PD-1-enriched CD3-CD56hiCD16-ve NK-cell phenotype is described, which can occur indirectly by PD-L1/PD-L2-expressing TAMs and contribute to the clinical sensitivity of cHL toPD-1 blockade.

TL;DR: Using a high-throughput sequencing screen to implement precision medicine at diagnosis can improve patient management and family counseling, and sheds light on newly recognized disease entities.

TL;DR: The DUO trial data support duvelisib as a potentially effective treatment option for patients with relapsed or refractory (RR) CLL/SLL and the overall response rate was significantly higher with duvel isib regardless of del(17p) status.

TL;DR: Findings in this exploratory study show that a preinfusion CAR product T-cell subset with a definable polyfunctional profile has a major association with clinical outcomes of CAR T- cell therapy.

TL;DR: Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible multiple myeloma.

TL;DR: It is concluded that nonclassical FD is caused by Fpn mutations that decrease hepcidin binding or hinder conformational changes required for ubiquitination and endocytosis of Fpn.

TL;DR: It is suggested here that treating or even preventing ARCH may prove to be beneficial for human health, as it remains unclear whether ARCH is a marker of aging or plays an active role in these various pathophysiologies.

TL;DR: It is indicated that ibrutinib may be associated with early-onset invasive fungal infections, in particular IA with frequent cerebral involvement, and that patients on ibrUTinib should be closely monitored in particular when other risk factors ofFungal infections are present.

TL;DR: NGS-based MRD is widely applicable to AML patients, is highly predictive of relapse and survival, and may help refine transplantation and posttransplantation management inAML patients.